Summary Report of Consolidated Financial Results
For the Three Months Period ended June 30, 2010

August 11, 2010
Company name: NIPRO CORPORATION
TSE/OSE–1st section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Minoru Sano, President and Representative Director
Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division
TEL: (06) 6372-2331
Filling date of quarterly reporting: August 13, 2010
Payment date of cash dividends: Supplemental material on quarterly reporting: None
Presentation on quarterly results: None
(Note: Amounts are truncated to one million yen)
1. Consolidated results for the three months ended June 30, 2010 (From April 1, 2010 to June 30, 2010)(1) Consolidated results of operations(Note: % of change from the same period a year ago)

Net Sales

Operating Income

Millions of yen%

Millions of yen%

45,061
43,620

3.3
2.6

4,772
4,056

17.7
16.9

3 months ended June 30,2010
3 months ended June 30,2009

Earnings per Share
3 months ended June 30,2010
3 months ended June 30,2009

Ordinary Income
Millions of yen

2,566
3,121

Net Income%

Millions of yen(17.8)(39.5)

1,348
1,322

%

2.0
(51.6)

Diluted Earnings per share

Yen

Yen

21.27
20.85

19.19
-

(2) Consolidated Financial Position

Total Assets

Millions of yen

371,864
383,396

114,284
116,070

112,340 million yen

Net Assets per
Share

Equity Ratio

Millions of yen
3 months ended June 30,2010
Year ended March 31, 2010
Note: Equity 3 months ended June 30, 2010

Net Assets

%

Yen

30.2
29.8

Year ended March 31, 2010

1,771.29
1,802.33

114,309 million yen

2. Dividends
Annual dividends per shareFirstquarter

Secondquarter
Yen-

Year ended March 31, 2010
Year ending March 31, 2011
Year ending March 31, 2011
(Forecast)Thirdquarter
Yen

Year-end
Dividends
Yen

Yen

Annualdividends
Yen

23.50

-

29.50

53.00

23.50

-

30.50

54.00

Note: Revisions to the forecast of cash dividends in the current quarter: No

3. Forecast of Consolidated Financial Results for the Year ending March 31, 2011 (From April 1, 2010 to March 31, 2011)(The % displays in the line of six months ending Sept. 30, 2010 show increase/decrease ratio against the six months ended
Sept.30, 2009. The % displays in the line of year ending March 31, 2011 show increase/decrease ratio against the year
ended March 31, 2010)
Operating
Ordinary
Earnings
Net Sales
Net Income
per Share
IncomeIncomeSix months ending Sept. 30, 2010
Year ending March 31, 2011

Millionsof yen%Millionsof yen%Millionsof yen%Millionsof yen%Yen

98,000206,000

12.1
15.8

7,800
17,200(15.8)(4.9)

6,600
15,300

(5.7)
2.6

3,300
7,900

(5.6)
8.9

52.03
124.56

Note: Revisions to the forecast of consolidated financial results in the current quarter: No

4. Others (For details, please refer to “2. Other information” on page 4 of attached documents.)(1) Change in significant subsidiaries during the current period: No(Note) Change in specified subsidiaries during the period that caused a change in the scope of consolidation(2) Adoption of accounting treatments simplified or unique for preparation : Yes(Note) Adoption of accounting treatments simplified and unique for preparation of quarterly consolidated financial
statements(3) Changes in accounting principles, procedures or presentation for consolidated financial statements[1] Changes by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No(Note) Changes in significant accounting principles, procedure and presentation which are to be stated in “Change insignificant matter of basis of preparation for consolidated financial statements”(4) Issued shares (Common stock)[1] Number of issued shares at end of the period (Including treasury stock):
3 months ended June 30, 2010: 63,878,505 sharesYear ended March 31, 2010: 63,878,505 shares[2] Number of treasury stock at end of the period:
3 months ended June 30, 2010: 455,498 sharesYear ended March 31, 2010: 455,328 shares[3] Average number of shares during the period:
3 months ended June 31, 2010: 63,423,116 shares
3 months ended June 30, 2009: 63,429,209 shares*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments and ExchangeAct. It is under the review procedure process at the time of disclosure of this report.

*Disclaimer regarding projection information including appropriate use of forecasted financial results, and other special notes
The projection figures shown above are based on information that was available at the time of preparation and may containcertain uncertainties. Actual performance and other factors may differ from these projections due to changes in circumstancesand other developments. More information concerning these forecasts can be found in P.4 “1. Qualitative information for thethree months period ended June 30, 2010, (3) Qualitative information concerning forecast of consolidated financial results” inthe attachments.

Table of contents

1. Qualitative information for the three months period ended June 30, 2010
(1)Qualitative information concerning consolidated financial results(2)Qualitative information on the consolidated financial position(3)Qualitative information concerning forecast of consolidated financial results

P.2
P.2
P.3
P.4

2. Other information(1)Overview of changes in significant consolidated subsidiaries(2)Overview of accounting treatments simplified or unique for preparation(3)Overview of changes in accounting principles, procedures, and disclosure for preparation

P.4
P.4
P.4
P.5

3. Consolidated financial statements(1)Quarterly consolidated balance sheets(2)Quarterly consolidated statements of income(3)Quarterly consolidated statements of cash flows(4)Notes related to going concern(5)Segment information(6)Notes to statements of shareholders’ equity, if having significant variation

P.6
P.6
P.8
P.9
P.11
P.11
P.14

-1-

1. Qualitative information for the three months period ended June 30, 2010
(1) Qualitative information concerning consolidated financial results
During the current quarter period ended June 30, 2010, despite the world economy showed a recovery trend
by the economic growth in the emerging country, we can not take such recovery for granted due to the turmoil
in the European financial markets and the sluggish U.S. economy.
The Japanese economy entered a self-sustaining recovery phase led by the private demand recovering
based on the increase of capital investments and exports. On the other hand, there still remains the uncertainty
about the recovery due to the concern about the application of yen and decline in stock prices.
Under such circumstances, we aimed to expand sales and production and continuously look to improve
production efficiency, all of which will help us improve our business performance.
Therefore, the consolidated sales in the first three months of fiscal year 2010(for the three month ended June30, 2010) increased 3.3% compared with the same period a year ago to 45,061million yen.
As for the profit, consolidated operating income increased 17.7% compared with the same period a year ago
to 4,772 million yen. Ordinary income decreased 17.8% compared with the same period a year ago to 2,566
million yen due to the influence of exchange rate fluctuations.Net income increased 2.0% compared with thesame period a year ago to 1,348 million yen.
The overviews of the results by segment in the current period are as follows.
[1] Medical businessOn the domestic side of medical business, we faced the overhaul of the medical fee scheme in April 2010.
The overhaul of the medical fee scheme in April 2010 was aiming to respond to the aggravation of the financial
condition of the health insurance system and economic situation. It became the upwardly-revised as a whole
for the first time in 10 years, aiming to resolve the medical crisis in these days and realize medical service
which provides people with a sense of security. However, official reimbursement price of drug and special
treatment materials was reduced 1.36% and our business and market conditions remained severe.
Sales grew greatly in vascular-related products (such as blood-clot trapping catheters, coronary artery stentand angiographic kit).In addition, sales of enteral alimentation-related products, injection- and infusion-related
products, dialysis related products (such as blood tube and dialysis solution) and testing-related products likeglucose analysis device grew steadily and made a profit under a severe business conditions.
On the international side of this business, the appreciation of Japanese yen against the U.S. dollar and Euroin addition to the sharp freight cost rises had great impact on our profit. Under such circumstances, we
continued to promote active sales promotion by strengthening our direct selling system in China where theeconomy is significantly growing, and to strengthen the community-based sales promotion in Latin Americanand Asian market so as to increase the sales amount.
Sales grew greatly in diabetic-related products, as well as the sales in dialysis-related product (such as
dialyzer, dialysis machine and blood tube) increased steadily by means of our active sales promotions in the
dialysis market such as in China. Furthermore, we trimmed the inventory level and improve sales efficiency so
as to deal with the increasing transportation cost and greatly improve our profitability.
As a result, net sales of this business were 29,737million yen.

-2-[2] Pharmaceutical businessIn pharmaceutical business, we have undertaken contract manufacturing business from many domestic andforeign pharmaceutical companies in addition to sales and manufacture of generic drug, taking advantage of
excellent manufacturing technologies of the pharmaceutical manufacture subsidiaries such as the Nipro
Pharma Corporation and the Tohoku Nipro Pharmaceutical Corporation, based on strong product development
capability of our company in pharmaceutical container and medical equipment.
While advancing our aging society and increasing in the number of institutions introducing the DPC(Diagnostic Procedure Combination) system, a comprehensive reimbursement system of medical costs forin-patients with acute stage conditions, the Nipro Pharma Corporation plays a central part in selling genericdrugs to promote sales of characteristic drugs and medicines expanding its range of merchandise thanks to thepolicies calling for the dissemination of generic products like the overhaul of medical fee scheme in April
2010.We registered steady sales growth in liquid-and-powder double-bag kits, pre-mixed-bag kits, injectabledrugs contained in plastic ampoules and oral drugs (such as orally disintegrating tablets and extended-releasetablets), as well as dialysis-related products (such as kit products of substitution fluid for hemofiltration andhemodiafiltration) getting a reputation by medical staff and patients.
In the field of contract manufacturing business, we undertook a lot of contract manufacturing projects with thecapable manufacturing plants of several dosage forms suitable to its drug, such as injectable drugs, oral drugs,
transdermal absorption drugs. In addition, we fully started contract manufacturing for steroid injectable drug
products and promoted new business in oral drugs with major pharmaceutical company. We also created aframework that enables us to provide a stable supply of high-quality products as the largest contract
manufacturer of pharmaceutical products in Japan.
As a result, net sales of this business were 9,220 million yen.
[3] Glass & Materials businessIn the field of glass materials, the sales of glass tube for pharmaceutical purpose increase as whole thanks to
the international sales promotion and increased demands in glass tube for glass bottles, though the domestic
demands in glass tube for pharmaceutical purpose decreased. Furthermore, we advanced establishment of
manufacturing bases in China and India. The export of glass for thermos bottles gradually showed the trend ofrecovery though the export mainly to markets in the Middle East decreased.
As for the sales of glass for lighting purposes, the sales of glass tube for electric lamp increased thanks to
the good condition in domestic production for automobile, on the other hand the sales of glass tube forbacklights decreased under the influence of penetration of LED products. In the filed of other pharmaceuticalcontainer, the sales of rubber stopper for pharmaceutical use and glass container for combination products(injectable lit products) increased as well as the sales of bags for antimicrobial agent and member of pre-filled
syringe increased steadily, based on our plastics, metal and rubber processing technologies.As for the
medicinal preparation and administration related device, we worked on joint development with pharmaceuticalcompanies to have a reputation. Furthermore, we have promoted contract manufacturing and development
cooperating with domestic and foreign pharmaceutical companies in general life cycle management ofpharmaceuticals entering the development of combination products, systematization for self-injection andmodification of dosage form in the view. In addition, the development and contract manufacturing of theinfluenza diagnostic kit to reagent manufacture companies progressed steadily.
As a result, net sales of this business were 5,998 million yen.
[4] Other businessIn the other business, the sales from real estate rental income were 105million yen.
(2) Qualitative information on the consolidated financial position[1] Analysis concerning the conditions of assets, liabilities and net assets
Total assets decreased 11,532 million yen from the end of the previous period to 371,864 million yen. Current
assets decreased 3,890 million yen and noncurrent assets decreased 7,642 million yen. Main reason for thedecrease in current assets was that cash and deposits decreased 10,417 million yen, and main reason for thedecrease in noncurrent assets was that investment securities decreased 25,261 million yen.

-3-

Total liabilities decreased 9,746 million yen to 257,579 million yen. Current liabilities decreased 7,774 million
yen and noncurrent liabilities decreased 1,972 million yen. Current liabilities decreased mainly due to thedecrease of 10,000 million yen in commercial papers and main reason for the decrease in noncurrent liabilities
was that deferred tax liabilities decreased 2,261 million yen.
Net assets decreased 1,786 million yen to 114,284 million yen from the end of the previous period.
Shareholders’ equity decreased 522 million yen and valuation and translation adjustments decreased 1,446
million yen.
[2] Analysis concerning the conditions of cash flows
The ending balance of cash and cash equivalents in the period under review decreased 10,279 million yen to45,908 million yen.
The conditions and main factors of each cash flow during the period under review were as follows.
(Cash flows from operating activities)
Net cash provided by operating activities was 2,170 million yen. The main accounts of cash inflow were net
income before adjustment of taxes, 2,872 million yen, depreciation and amortization, 4,337 million yen. The
main accounts of cash outflow were increase of inventories, 1,943 million yen, and payment of corporate
income tax, 4,472 million yen.
(Cash flows from investing activities)
Net cash used in investing activities was 4,269 million yen. The main account of cash outflow was purchase ofnoncurrent assets 4,268 million yen.
(Cash flows from financing activities)
Net cash used in investing activities was 9,588 million yen. The main accounts of cash inflow were proceedsfrom long-term loans payable, 5,849 million yen. The main accounts of cash outflow were decrease incommercial papers, 10,000 million yen, and repayment of long-term loans payable, 4,679 million yen.

(3)Qualitative information concerning forecast of consolidated financial results
In the world economy in the future, the forecast of U.S. economy continues to remain uncertain and theeconomic activities in emerging countries and resource-rich country might have a strong impact on sharp
exchange rate fluctuations. In the Japanese economy, impact of a shrinking and aging population and declining
fertility and the decrease of domestic demands based on the restoring of public fiscal health are expected.
At this moment, there is no revision to the forecast of consolidated financial results for the FY2010 which was
published May 14, 2010.
2. Other information(1)Overview of changes in significant subsidiaries
N/A(2) Overview of accounting treatments simplified or unique for preparation[1] Simplified accounting procedures
1) Calculation of estimated impairment for general receivables
As it was accepted that there was no significant change between the actual rate or index of bad debts accrual
calculated at the end of the current quarterly consolidated accounting period and at the end of the previous
consolidated accounting year, the later rate or index was utilized for estimation of impairment of general
receivables.

-4-2) Measurement for inventory
As for the inventory amount at end of the current quarterly consolidated accounting period, actual stock
counting procedure was omitted and the inventory amount was calculated by the reasonable method based on
the actual stock balance at end of the previous consolidated accounting year.
3) Calculation method for depreciation of noncurrent assets
The noncurrent assets depreciated in declining balance method were calculated by prorating the depreciation
amount in the consolidated accounting year.
4) Deferred tax assets and liabilities
As for the judgment of collectability of deferred tax assets, the forecasted financial results and tax planning
used in the end of the previous consolidated accounting year was utilized, as it was accepted that there was no
significant change in the situation of accrued temporally differences from the end of the previous consolidated
accounting year.
[2] Accounting procedures unique for preparation of quarterly consolidated financial statements: N/A(3) Overview of changes in accounting principles, procedures, and disclosure for preparation[1] Change in accounting principles(Application of Revised Accounting Standard for Equity Method of Accounting for Investments)
Effective from the first quarter of FY2010, the Company has applied the Revised Accounting Standard for
Equity Method of Accounting for Investments (Accounting and Standards Board of Japan (ASBJ) Statement No.
16, issued March 10, 2008) and the Practical Solution on Unification of Accounting Policies Applied to
Associates Accounted for Using the Equity Method (Practical Issues Task Force (PITF) No. 24, issued March
10, 2008). There is no impact on profit and loss regarding to this change.
(Application of Accounting Standard for Asset Retirement Obligations)
Effective from the first quarter of FY2010, the Company has applied the Accounting Standard for Asset
Retirement Obligations (ASBJ Statement No. 18, issued on March 31, 2008) and Guidance on AccountingStandard for Asset Retirement Obligations (ASBJ Guidance No. 21, issued on March 31, 2008).
The impact of this change was to reduce both operating income and ordinary income for the quarter period by
2 million yen and income before income taxes by 95 million yen.
(Application of Accounting Standards for Business Combinations)
Effective from the first quarter of fiscal 2010, the Company has applied Accounting Standard for Business
Combinations (ASBJ Statement No. 21), issued on December 26, 2008; Accounting Standard for Consolidated
Financial Statements (ASBJ Statement No. 22), issued on December 26, 2008; Partial Amendments to
Accounting Standard for Research and Development Costs(ASBJ Statement No. 23), issued on December 26,
2008; Revised Accounting Standard for Business Divestitures (ASBJ Statement No. 7, revised 2008), issued
on December 26, 2008; Revised Accounting Standard for Equity Method of Accounting for Investments (ASBJ
Standard No. 16, revised 2008), issued on December 26, 2008; and Revised Guidance on AccountingStandard for Business Combinations and Accounting Standard for Business Divestures (ASBJ Guidance No.
10, revised 2008),issued on December 26, 2008. There is no impact on profit and loss regarding to thischange.
[2] Change in accounting principles(Overview of changes in significant consolidated subsidiaries)
As a result of the application of the Cabinet Office Ordinance Partially Revising Regulation on Terminology,
Forms and Preparation of Financial Statements (Cabinet Office Ordinance No.5, March 24, 2009) based on the
Accounting Standard for Consolidated Financial Statements (ASJB Statements No. 22 of December 26, 2008),
the item “Net income before adjustment for minority interests” is included in the financial statements in thisfiscal period.
-5-

3. Consolidated Financial Statements(1) [ Consolidated Balance Sheets ](Amount: million yen)

As ofJune 30, 2010
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery, equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Guarantee deposits
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-6-

As of
March 31, 2010

48,84959,29339,826
7,436
11,203
2,806
7,060
(438)
176,038

59,26656,30338,503
6,192
10,008
3,149
6,937
(432)
179,928

108,881(58,082)
50,798125,424(85,602)39,822
19,836
1,456
(237)
1,219
12,71425,990(21,191)
4,799
129,190

107,011(56,495)
50,515
117,534(81,395)
36,13819,766
1,393
(173)
1,220
11,99225,032(20,456)
4,575
124,208

12,74485
1,957
14,787

561
78
1,736
2,376

47,614
664
4,034
2,718
(3,184)
51,848
195,826
371,864

72,875
334
4,071
2,788
(3,186)76,883
203,468
383,396

(Amount: million yen)

As ofJune 30, 2010
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bonuses
Income taxes payable
Provision for bonuses
Provision for directors' bonuses
Provision for loss on business liquidation
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Convertible bond-type bonds
with subscription rights to shares
Long-term loans payable
Lease obligations
Deferred tax liabilities
Provision for retirement benefits
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Valuation and translation adjustments
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total valuation and translation adjustments
Minority interests
Total net assets
Total liabilities and net assets

-7-

As of
March 31, 2010

31,35666,756
10,160
331
5,144
1,216
981
75
1,954
3,586
8,866
130,430

29,20364,442
10,00010,160
318
5,792
204
4,932
1,758
23
1,954
3,869
5,543
138,204

28,00028,00015,00015,00072,808
1,085
5,509
2,152
622
170
1,801
127,149
257,579

72,839
1,098
7,771
1,972
614
170
1,655
129,121267,325

28,66329,972
46,697(862)
104,471

28,66329,972
47,219(862)
104,993

11,673(3,804)
7,869
1,943
114,284
371,864

15,024(5,708)9,316
1,761
116,070
383,396(2) [ Consolidated Statements of Income ](Amount: million yen)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Depreciation
Foreign exchange losses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Gain on prior period adjustment
Compensation income
Licensed dealership charges
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Abnormal manufacturing cost

FY2009 first three months(From April 1, 2009
to June 30, 2009)
43,62031,34012,2808,224
4,056

FY2010 first three months(From April 1, 2010
to June 30, 2010)
45,061
31,226
13,834
9,062
4,772

55
304
129
489

77
325
122
525

560
69
311
444
37
1,423
3,121

586
1,902
136
104
2,730
2,566

12
8
4
26

6
2
122
300
73
504

7
228

19
55

-

92

89
326
2,821
1,167
227
1,395
103
1,322

30
198
2,872
739
661
1,401
1,471
122
1,348

Loss on adjustment for changes of accounting
standard for asset retirement obligations
Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Income before minority interests
Minority interests in income
Net income-8-(3) [ Consolidated Statements of Cash Flows ](Amount: million yen)
FY2009 first three months FY2010 first three months(From April 1, 2009
(From April 1, 2010
to June 30, 2009)
to June 30, 2010)
Net cash provided by (used in) operating activities
Income before income taxes and minority interests
Depreciation and amortization
Impairment loss
Amortization of goodwill
Equity in (earnings) losses of affiliates
Increase (decrease) in allowance for doubtful accounts
Interest and dividends income
Interest expenses
Foreign exchange losses (gains)
Decrease (increase) in notes and accounts receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Decrease (increase) in other assets
Increase (decrease) in other liabilities
Other loss (gain)
SubtotalInterest and dividends income received
Interest expenses paid
Other proceeds
Other payments
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of investment securities
Purchase of noncurrent assets
Proceeds from sales of noncurrent assets
Proceeds from governmental subsidies
for investment in property and equipment
Net Decrease (increase) in short-term loans receivable
Payments of loans receivableCollection of loans receivable
Other proceeds
Net cash provided by (used in) investment activities

-9-

2,821
4,076
72
444
25
(360)
560
99
(3,567)
(153)
3,605
579
(1,155)
27
7,078
441
(420)
139
(57)
(1,847)
5,333

2,872
4,337
19
446
136
3
(402)
586
249
(833)
(1,943)
1,444
684
(906)
(38)
6,656
362
(405)
203
(173)
(4,472)
2,170

(318)
1,170
(0)
(14,772)
27

(640)
802
(50)
(4,268)
21

202

25

686
0
2
(13,003)

(147)
(15)
3
(4,269)(Amount: million yen)
FY2009 first three months FY2010 first three months(From April 1, 2009
(From April 1, 2010
to June 30, 2009)
to June 30, 2010)
Net cash provided by (used in) financing activities
Net increase (decrease) in short-term loans payable
Increase (decrease) in commercial papers
Proceeds from long-term loans payable
Repayment of long-term loans payable
Decrease (increase) in treasury stock
Repayments of finance lease obligations
Cash dividends paid
Cash dividends paid for minority shareholders
Other payments
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Increase in cash and cash equivalentsfrom newly consolidated subsidiary
Cash and cash equivalents at end of period- 10 -

6,589
500(4,818)
(8)
(25)
(1)
(2)
(21)
2,211
(372)
(5,830)45,532

1,020(10,000)
5,849(4,679)(0)(86)(1,684)(3)(6)(9,588)(186)(11,874)
56,188-

1,595

39,52245,908

(4) Notes related to going concern
N/A(5) Segment information<Segment information by business category>
FY2009 (From April 1, 2009 to June 30, 2009)(Millions of yen)

MedicalEquipment

Pharmaceutical

Glass &
Materials(1)Sales to third parties

27,093

14,225

2,052

249(2)Inter-segment sales
and transfers

-

0

974

27,093

14,225

3,950

1,317

Eliminations/Corporate

Consolidated

43,620-43,620

21

996

(996)

-

3,027

270

44,617(996)

43,620

436

10

5,714

(1,658)

4,056

Other

Total

Net sales

Total
Operating income

Notes: 1. Classification of business categories and main products in each business category
Business categories are classified based on the proximity in terms of purposes andmanners of usage of the products in the market.
Main products belonging to each business category are as follows:Business
category
MedicalEquipment

Main products and commodities
Dialyzers, blood tubing sets, injection needles, syringes, and infusion sets,
etc.

Pharmaceutical

Half-type and full-type kits, double-bag kits, pre-filled syringes, dialysis
solution, and circulatory drugs, etc.

Glass & Materials

Glass for pharmaceutical containers, glass for thermos bottles, glass forlighting purposes, stoppers for plastic containers and rubber stoppers, etc.

Other

Machinery for manufacture of medical equipment and real estate rental
income, etc.

- 11 -

<Segment information by geographical area>
FY2009 (From April 1, 2009 to June 30, 2009)
Japan

America(Millions of yen)
Asia

EuropeTotal

Eliminations/Corporate

Consolidated

Net sales(1) Sales to third parties

34,526

4,503

2,995

1,594

43,620-43,620(2) Inter-segment sales
and transfers

6,587

203

0

3,743

10,534(10,534)-

Total

41,114

4,706

2,995

5,338

54,155(10,534)

43,620Operating income (loss)

5,403

(49)

36

600

5,990

(1,934)

4,056

Notes:

1.

Classification of countries or areas is based on geographical proximity.

2.

The major countries included in each geographical area are as follows:
America……..
Europe………
Asia………….

The United States of America and Brazil
Belgium
China, Thailand and Singapore<Overseas sales>
FY2009 (From April 1, 2009 to June 30, 2009)

1. Overseas sales(Millions of yen)

America

Europe

Asia

Total

7,275

4,914

2,383

14,573

2. Consolidated net sales
3. Percentage of overseas sales toconsolidated net sales (%)

Notes:

43,620

16.7％

11.3%

5.4％

33.4％

1.

Overseas sales represent those of the Company and the consolidated subsidiaries to countries
and areas outside of Japan.

2.

Classification of countries or areas is based on geographical proximity.

3.

The major countries included in each geographical area are as follows:
America ·············· The United States of America, Canada and Brazil
Europe················ Belgium, Denmark and Germany
Asia ···················· China, India, Indonesia, Taiwan and Thailand- 12 -

<Segment information>
1. Outline of reportable operating segments
The reportable operating segments are components of an entity for which separate financial information isavailable and evaluated regularly by the board of director in determining the allocation of management
resources and in assessing performance.
We currently operate our business on a stand-alone basis with the divisional organization and evaluate theperformance of sales and manufacture of each division regardless of their products. Accordingly, we divide ouroperations into 3 reportable operating segments on the basis of its main products: Medical, Pharmaceuticals
and Glass & Materials.
*MedicalDomestic division sells injection- and infusion-related products, artificial organ-related products,
highly functional products, dialysis-related products and diabetic-related products.
In the international division, head office plays the center role and place overseas sales andmanufacturing base for medical equipment and sales injection- and infusion-related products,
artificial organ-related products and diabetic-related products.
*Pharmaceutical
Mainly, domestic subsidiaries sell and manufacture injectable drug, oral drugs and products bycontract manufacturing like combination products (Kit injectable).
*Glass & Materials
In the field of glass for pharmaceutical purposes, we sell glass for glass tube, glass forampoule. In the field of glass & materials products, we sell glass for thermos bottles and glass forlighting purpose. In addition, we sell container for combination products and undertake thecontract sales of pharmaceuticals related to the container for combination products frompharmaceutical company.
2. Sales and profit by reportable operating segments
FY2010 (From April 1, 2010 to June 30, 2010)(Millions of yen)Segment
Other
Note.1

Total

Adjustment
Note.2

Consolidated
statements ofincomeNote.3

MedicalPharmaceutical

Glass &
Materials

Total(1)Sales to third parties

29,737

9,220

5,998

44,956

105

45,061-45,061(2)Inter-segment sales
and transfers

54

4,398

972

5,424

9

5,434

(5,434)-

Total

29,791

13,618

6,971

50,380115

50,496(5,434)45,061

Segment profit

5,287

724

665

6,678

21

6,700

(1,927)

4,772

Net sales

Notes:

1.

“Other” is the business segment which is not included in the reporting segment and consist ofreal estate income and sales by headquarter.

2.

Adjustment for the segment profit of (1,927) million yen includes corporate cost of (1,937) million
yen and elimination of inter-segment transaction of 10 million yen. Corporate cost consisted
primarily of sales, general and administrative expenses and research and development costwhich do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

3.

3. Information on goodwill by reportable operating segments(Significant variation in the amount of goodwill)
We included the Nipro Diagnostics, Inc. and other 3 companies in the scope of consolidation.
The regarding increase in the amount of goodwill was 12,264 million yen compared with theprevious period.

- 13 -

(Additional information)
Effective from the first quarter ended June 30, 2010, we have applied the revised AccountingStandard for Disclosures about Segments of an Enterprise and Related Information (ASBJ Statement
No. 17, issued March 27, 2009) and Guidance on Accounting Standard for Disclosures about
Segments of an Enterprise and Related Information (ASBJ Guidance No. 20, issued March 21, 2008).

(6)Notes to statements of shareholders’ equity, if having significant variation
N/A- 14 -